In order to gather stakeholder input on the initiatives explained in the Biosimilar Action Plan unveiled by FDA Commissioner Scott Gottlieb, MD, last week, the FDA has announced that it will hold a public hearing on the plan on September 4, 2018.
In order to gather stakeholder input on the initiatives explained in the Biosimilar Action Plan unveiled by FDA Commissioner Scott Gottlieb, MD, last week, the FDA has announced that it will hold a public hearing on the plan on September 4, 2018.
The action plan addressed 4 key areas intended to improve biosimilar competition:
The “FDA is soliciting input from the public on how to facilitate greater availability of biosimilar and interchangeable products while retaining the balance between competition and innovation that Congress intended to achieve under the [Biologics Price Competition and Innovation Act],” according to the agency’s announcement. In particular, the FDA is interested in how it can leverage its existing statutory authority to regulate biologics and biosimilars to address issues around the current lack of competition in the market.
Within the announcement, the FDA listed specific questions on which it would like to receive stakeholder feedback, including how the agency can help biosimilars reach patients more quickly after approval, what additional information should be included in the Purple Book to make it more useful, what new steps the agency can take to facilitate evolution of the biologics and biosimilars marketplace, what the agency can do to help reduce development costs without sacrificing safety and quality of biosimilars, how the agency can facilitate multinational development programs that may include reference products licensed outside the United States, and how the FDA can ensure that changes to biologics do not inappropriately deter biosimilar competition.
Electronic comments may be submitted to the Federal Register until September 21, 2018.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.